Sign Out
Pregnancy: There are no data from the use of lercanidipine in pregnant women. Studies in animals have not shown teratogenic effects (see Pharmacology: Toxicology: Preclinical safety data under Actions), but these have been observed with other dihydropyridine compounds. Lercanidipine is not recommended during pregnancy and in women of childbearing-potential not using contraception.
Breast-feeding: It is unknown whether lercanidipine/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Lercanidipine should not be used during breast-feeding.
Fertility: No clinical data are available with lercanidipine. Reversible biochemical changes in the head of spermatozoa which can impair fecundation have been reported in some patients treated by channel blockers. In cases where repeated in-vitro fertilization is unsuccessful and where another explanation cannot be found, the possibility of calcium channel blockers as the cause should be considered.
